Business Wire

2020: Our Extraordinary Year in DiDi Numbers

29.1.2021 04:00:00 EET | Business Wire | Press release

Share

2020 was a year like no other for the world, for DiDi’s nearly 600 million users and driver partners, as well as its 13,000 corporate employees. At the dawn of a new year of hope, we would like to take some time to look back at some of the highlights in 2020 to celebrate the resilience of our people and cities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128006172/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

DiDi 2020 in Numbers (Graphic: Didi Chuxing)

  • Protecting local communities is our utmost priority.

Offline, more than 11 million sets of free masks and sanitizers were distributed to millions of drivers and couriers worldwide throughout 2020. DiDi driver-managers helped install 1 million protective dividers in DiDi cars to prevent droplet infection. Hi-tech or low-tech, we went the full distance for tech that works.

Online, all of DiDi’s 30 million+ driver partners went through a Health Guard routine that includes mask, temperature and disinfection checks to log onto daily service.

We stand ready to help our cities. Globally, hundreds of thousands of DiDi drivers and couriers provided more than 6 million free or discounted rides and meals to frontline health care workers and those in need. From mask verification to contact tracing, our engineers open-sourced various technological tools for cities around the world.

  • Our safety standards are higher and stronger.

Internationally, major safety incidents on DiDi dropped by 50.8% year-on-year. In-trip disputes and conflicts were down by 42.3%. Sexual-related complaints dropped by 71.4%.

This was made possible by continued safety investments. Across our international markets, DiDi’s risk analysis and management algorithms activated over 361 million control acts ranging from safety reminders, extra verifications, warnings and all the way to geo-fencing and active individual interventions.

But we couldn’t have done it without you and your safety awareness. Drivers and riders outside China chose to activate advanced safety options over 25 million times. In-trip audio recording was used over 1.3 million times. Over 23 million trips were shared with trusted ones.

  • With these solid health and safety bottom lines, we helped build stronger and more inclusive communities.

Globally, over 4 million drivers and couriers registered to use DiDi’s platform in 2020, many of whom were looking for extra income opportunities to tackle the challenges arising from the pandemic. Of the newly registered driver partners in international markets in 2020, 13.6% are women. Together with our female employees that account for 40% of DiDi’s workforce, women drivers helped us build higher platform standards of diversity and inclusion.

  • Together with these partners, we were able to stay resilient and achieve new growth.

Global daily trips hit a new record high of 60 million in October 2020. We also launched multiple new services including group-buying, courier, and freight businesses to capture demands arising from new consumer dynamics. As businesses focus more on efficiency, DiDi Enterprise Solutions, which helps cut employee and business transportation costs, also saw a 12% year-on-year growth in its client base.

In 2020, six new markets were opened – Russia, Peru, Panama, Argentina, the Dominican Republic and New Zealand. Trips completed outside China reached 1 billion.

  • Finally, our numbers also reflected special moments of life in every city we operate:

    • Small businesses are true warriors: A food shop-owner in Brazil, our star user globally, completed 2,017 trips in 2020 for in-person delivery.
    • There is always one long ride we have to take in life: A Brazilian user took a trip of 999.7 kilometers in 2020.
    • Good food comforts us and makes things right: The most frequent DiDi Food user, a Mexican gourmet, completed 749 orders from 216 restaurants in 2020.
    • The most popular time of the day to place a food delivery order was 3pm in Mexico, 7pm in Japan and 8pm in Brazil.
    • In 2020, the most ordered items in Japan, Mexico and Brazil was large-size beef noodles, traditional pepperoni pizza, beef and chicken burger, respectively.

In times of uncertainty, we heard more stories of love, perseverance and our shared fighting spirit. Kudos to all! We will be back together, back stronger as 2021 brings renewed hopes and commitments.

About Didi Chuxing

Didi Chuxing (“DiDi”) is the world’s leading mobile transportation and local services platform. The company offers a full range of app-based services for over 550 million users across Asia Pacific, Latin America and Russia, including taxi-hailing, private car-hailing, P2P rideshare, bus, bikes & e-bikes, designated driving, automobile solutions, delivery and logistics, and financial services. Tens of millions of car owners, drivers and delivery partners who find flexible work and income opportunities on DiDi platform provide over 10 billion passenger trips a year. Daily trip volume for DiDi’s core mobility services exceeds 60 million during the first week of October 2020.

DiDi is committed to collaborating with policymakers, the taxi industry, the automobile industry and our communities to solve the world’s transportation, environmental and employment challenges with localized smart transportation innovations by leveraging its AI capabilities. We will strive non-stop to create better life experience and greater social value, through building a safe, inclusive and sustainable transportation and local services ecosystem for cities of the future.

For more information, please visit: www.didiglobal.com/news.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiry:

Didi Chuxing
globalpr@didiglobal.com

Sard Verbinnen & Co
DidiChuxing@sardverb.com
US +1 415 618 8750
HK +852 3842 2200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye